Pure Global AI
NCT06390098Completed

Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51

A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Adult Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51 Following a Single Oral Dose
Asceneuron S.A.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Alzheimer Disease
Drug/Device/Intervention
ASN51
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Asceneuron S.A.
Location
London, United Kingdom
Timeline & enrollment
Phase
Phase 1
Start date
Aug 09, 2021
End date
Nov 02, 2021
Enrollment
3 participants
Primary outcome

Pharmacodynamic (PD) change of [18F]-IMA601 regional total volume of distribution (VT) at each brain scan

Summary

This is a phase 1, open-label, PET study in healthy adult subjects to determine the
 relationship between plasma concentration and brain target occupancy of ASN51 following a
 single oral dose.

ICD-10 classifications
Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06390098
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06390098 through Pure Global AI's free database. This Phase 1 trial is sponsored by Asceneuron S.A. and is currently Completed. The study focuses on Alzheimer Disease. Target enrollment is 3 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.